Tinnitus Update
I presented the Microtransponder story to the Institute for Innovation and Entrepreneurship at UT-Dallas and once again I had a number of tinnitus sufferers approach me about our progress in translating the therapy. My heart goes out to these patients, as every story I hear about their symptoms are worse than the last. I also have to give credit to the Tinnitus chat rooms/message boards… apparently the results are being actively discussed there…albeit the information is sometimes wildly inaccurate, perhaps due to my deficiencies as a writer (the proofreader blows up when I try to post)…I learned as a baseball player not to follow the message boards, so I won’t spend time correcting/addressing issues there. I need all of my energy and confidence focused on moving the therapy forward.
The good news is that we have a very compelling story coming together in the clinic. We expect to need to show a 50% response rate (meaning 4 out of 8 patients) that have shown substantial relief (we are currently 5 out of 7). We would expect this number to get better as we get better at selecting patients for the trial (there is potentially a very interesting method we discovered to do this). However, it is challenging to find objective imaging or diagnostic tools that can measure the changes occurring in the brain. More on this here (luckily the lead author Rich Tyler is consulting on our current trial design and how best to design our next trial).
http://www.ncbi.nlm.nih.gov/pubmed/17956814
http://www.ncbi.nlm.nih.gov/pubmed/17114142
We met with a number of experts at the Buffalo Tinnitus workshop in August, who were very impressed with the data and our scientific team. This input has lead to a fairly major shift in our strategy as our Board of Directors (BOD) has decided to focus our remaining investment dollars for a commercial device for tinnitus. This is in part due to the clinical signal we have observed, but also due to the overwhelming survey results demonstrating a significant unmet need for an implantable solution (everyone would take a pill that costs a dollar, but the question for our BOD was whether they would have surgery).
Our tasks now are to wrap-up the feasibility study in Belgium and begin planning a larger overseas study. We also plan to put a grant request in to the NIDCD to support a US, multi-center study. My task now is to coordinate our clinical trial designs with the sites and the FDA. I’m also tasked with raising a small supplement to our current round of funding. We are targeting a $3M extension of our current round, which should be enough (if we get the grant) to get a CE Mark for the tinnitus product and begin sales of the Tinnitus therapy in Europe. The U.S. approval will be after Europe due to FDA regulatory requirements.
We expect to present our data at a conference soon, along with a peer reviewed publication in 2012.

September 19, 2011 











